CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...